Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy ; volume:14 ; number:2 ; day:13 ; month:2 ; year:2024 ; pages:277-289 ; date:3.2024
Health and Technology ; 14, Heft 2 (13.2.2024), 277-289, 3.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Wyk, Bronwin Van
Hasford, Francis
Nyakale, Nozipho
Vangu, Mboyo-Di-Tamba
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12553-024-00818-x
- URN
-
urn:nbn:de:101:1-2404291311003.597557245976
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wyk, Bronwin Van
- Hasford, Francis
- Nyakale, Nozipho
- Vangu, Mboyo-Di-Tamba
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Adsorption behavior of in-house developed CO2-philic anionic surfactants
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Publisher Correction: Adsorption behavior of in-house developed CO2-philic anionic surfactants
Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Inhouse Consulting
Inhouse-Systeme
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
Radionuclide
Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Adsorption behavior of in-house developed CO2-philic anionic surfactants
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Publisher Correction: Adsorption behavior of in-house developed CO2-philic anionic surfactants
Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Inhouse Consulting
Inhouse-Systeme
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
Radionuclide
Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Adsorption behavior of in-house developed CO2-philic anionic surfactants
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Publisher Correction: Adsorption behavior of in-house developed CO2-philic anionic surfactants
Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
Inhouse Consulting
Inhouse-Systeme
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
Radionuclide